Anavex Strongly focused
  on increasing value
HOME  |  ABOUT US  |  PIPELINE  |  R & D  |  PUBLICATIONS  |  PARTNERING  |  INVESTORS  |  CAREERS  |  CONTACT

Stock Quote
Share Information
Press Releases
SEC Filings
Code of Conduct
Investor Kit
Biopharma Industry
Media
 
Press Releases
Date   Title
March 31, 2014
 
March 27, 2014
 
March 19, 2014
 
March 13, 2014
 
March 10, 2014
 
March 4, 2014
 
February 26, 2014
 
February 3, 2014
 
January 23, 2014
 
January 13, 2014
 
January 7, 2014
 
December 10, 2013
 
December 3, 2013
 
November 21, 2013
 
November 20, 2013
 
November 18, 2013
 
November 12, 2013
 
November 7, 2013
 
November 4, 2013
 
October 29, 2013
 
October 22, 2013
 
September 23, 2013
 
September 03, 2013
 
August 15, 2013
 
July 08, 2013
 
May 06, 2013
 
March 18, 2013
 
March 12, 2013
 
February 4, 2013
 
January 10, 2013
 
October 18, 2012
 
October 12, 2012
 
September 21, 2012
 
July 17, 2012
 
July 09, 2012
 
June 26, 2012
 
May 30, 2012
 
February 14, 2012
 
November 14, 2011
 
October 12, 2011
 
September 16, 2011
 
September 15, 2011
 
July 26, 2011
 
July 25, 2011
 
July 15, 2011
 
July 11, 2011
 
July 6, 2011
 
June 8, 2011
 
May 23, 2011
 
May 17, 2011
 
May 14, 2011
 
April 20, 2011
 
April 8, 2011
 
March 31, 2011
 
March 16, 2011
 
March 15, 2011
 
March 1, 2011
 
February 23, 2011
 
February 16, 2011
 
January 18, 2011
 
January 6, 2011
 
December 21, 2010
 
September 30, 2010
 
September 13, 2010
 
September 8, 2010
 
August 30, 2010
 
August 10, 2010
 
May 4, 2010
 
January 18, 2010
 
September 30, 2009
 
September 21, 2009
 
August 27, 2009
 
June 16, 2009
 
April 08, 2009
 
February 10, 2009
 
January 30, 2009
 
December 17, 2008
 
December 4, 2008
 
September 2, 2008
 
July 30, 2008
 
June 24, 2008
 
June 3, 2008
  Anavex further strengthens Board of Directors
May 21, 2008
  Anavex Announces Appointment of Oncology Specialist
to Board of Directors
March 10, 2008
  ANAVEX 7-1037 reduces rate of cancer tumor growth 69%
in preclinical studies, compared to currently marketed
drug Dacarbazine showing no measurable activity
January 22, 2008
  Anavex outlines corporate milestones, drug advancement
plans for 2008
December 17, 2007
  Anavex strengthens Board of Directors
December 11, 2007
  ANAVEX 7-1037 demonstrates chemotherapeutic potential without toxic side effects for the treatment of colorectal cancer, other types of solid tumors
December 6, 2007
  Anavex advances drug candidates for treatment of epilepsy
November 28, 2007
  Anavex advances drug candidate for treatment of Alzheimer’s disease
November 2, 2007
  Anavex Life Sciences engages Primoris Group to provide
investor relations services
June 5, 2007
  Annual General Meeting of the shareholders of Anavex
Life Sciences Corp.
May 23, 2007
  Preclinical Data of ANAVEX 1-41 and ANAVEX 2-73,
Show Highly Potent Anti-Amnesic and Neuroprotective
Activity Against Amyloid Beta (25-35) Peptide Toxicity
in Alzheimer’s Disease (AD) Animal Models
.
April 16, 2007
  Dr. Jean Jacques Bourguignon Joins Anavex Life Sciences
Corp. Scientific Team
April 2, 2007
  Anavex Life Sciences Corp. Announces Research Agreement With University of Paris 5-Rene Descartes
February 12, 2007
  Anavex Life Sciences Corp. Announces Its Preclinical
Pipeline of Novel Oncology Therapies
February 7, 2007
  Anavex Life Sciences Corp. Appoints VP Business Development and VP Strategic Planning
February 1, 2007
  Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
January 31, 2007
  Anavex Life Sciences Corp. Acquires a Portfolio of Patents
and Appoints Dr. Alexandre Vamvakides as CSO and Director
January 25, 2007
  Anavex Life Sciences Corp.: Appointment of CEO and Director
© 2007-2014 Anavex Life Sciences Corp. - All Rights Reserved.